← Back to home

ANTI-3-HYDROXY-3-METHYLGLUTARYL-COA REDUCTASE (HMGCR) IMMUNE-MEDIATED NECROTIZING MYOPATHY

Clinical trials for ANTI-3-HYDROXY-3-METHYLGLUTARYL-COA REDUCTASE (HMGCR) IMMUNE-MEDIATED NECROTIZING MYOPATHY explained in plain language.

Never miss a new study

Get alerted when new ANTI-3-HYDROXY-3-METHYLGLUTARYL-COA REDUCTASE (HMGCR) IMMUNE-MEDIATED NECROTIZING MYOPATHY trials appear

Sign up with your email to follow new studies for ANTI-3-HYDROXY-3-METHYLGLUTARYL-COA REDUCTASE (HMGCR) IMMUNE-MEDIATED NECROTIZING MYOPATHY, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Trials to join now! 1

Experimental treatment trial launches for devastating Muscle-Wasting disease

Disease control Recruiting now

This trial is testing whether intravenous immunoglobulin (IVIG) can help control anti-HMGCR immune-mediated necrotizing myopathy, a rare autoimmune disease where the immune system attacks muscle tissue. Twelve participants with active disease will receive either IVIG or a placebo…

Matched conditions: ANTI-3-HYDROXY-3-METHYLGLUTARYL-COA REDUCTASE (HMGCR) IMMUNE-MEDIATED NECROTIZING MYOPATHY

Phase: PHASE2 • Sponsor: University of Alabama at Birmingham • Aim: Disease control

Last updated Mar 30, 2026 14:30 UTC

ANTI-3-HYDROXY-3-METHYLGLUTARYL-COA REDUCTASE (HMGCR) IMMUNE-MEDIATED NECROTIZING MYOPATHY

Get alerted when new ANTI-3-HYDROXY-3-METHYLGLUTARYL-COA REDUCTASE (HMGCR) IMMUNE-MEDIATED NECROTIZING MYOPATHY trials appear

Experimental treatment trial launches for devastating Muscle-Wasting disease